메뉴 건너뛰기
Journal of Neuro-Oncology
Volumn 95, Issue 2, 2009, Pages 299-300
Bevacizumab in adult malignant brainstem gliomas
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN INHIBITOR;
EID: 70350028348     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9933-1     Document Type: Letter
Times cited : (7)
References (7)
  • 1
    • 67349215184 scopus 로고    scopus 로고
    • Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: Case report
    • doi: 10.1007/s11060-008-9782-3
    • Torcuator R, Zuniga R, Loutfi R, et al (2009) Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: Case report J Neurooncol. doi: 10.1007/s11060-008-9782-3
    • (2009) J Neurooncol
    • Torcuator, R.1    Zuniga, R.2    Loutfi, R.3
  • 2
    • 40149089980 scopus 로고    scopus 로고
    • Natural history and management of brainstem gliomas in adults. A retrospective Italian study
    • doi: 10.1007/s00415-008-0589-0
    • Salmaggi A, Fariselli L, Milanesi I et al (2008) Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol 255:171-177. doi: 10.1007/s00415-008-0589-0
    • (2008) J Neurol , vol.255 , pp. 171-177
    • Salmaggi, A.1    Fariselli, L.2    Milanesi, I.3
  • 3
    • 0035211709 scopus 로고    scopus 로고
    • Brainstem gliomas in adults: Prognostic factors and classification
    • Guillamo JS, Monjour A, Taillandier L et al (2001) Brainstem gliomas in adults: Prognostic factors and classification. Brain 124(Pt-12):2528-2539
    • (2001) Brain , vol.124 , Issue.PART 12 , pp. 2528-2539
    • Guillamo, J.S.1    Monjour, A.2    Taillandier, L.3
  • 4
    • 43149122874 scopus 로고    scopus 로고
    • Prognostic factors in adult brainstem gliomas: A multicenter, retrospective analysis of 101 cases
    • doi: 10.1007/s11060-008-9545-1
    • Kesari S, Kim RS, Markos V et al (2008) Prognostic factors in adult brainstem gliomas: A multicenter, retrospective analysis of 101 cases. J Neurooncol 88:175-183. doi: 10.1007/s11060-008-9545-1
    • (2008) J Neurooncol , vol.88 , pp. 175-183
    • Kesari, S.1    Kim, R.S.2    Markos, V.3
  • 6
    • 41649112610 scopus 로고    scopus 로고
    • Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
    • doi: 10.1212/01.wnl.0000304121.57857.38
    • Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779-787. doi: 10.1212/01.wnl.0000304121.57857.38
    • (2008) Neurology , vol.70 , Issue.10 , pp. 779-787
    • Norden, A.D.1    Young, G.S.2    Setayesh, K.3
  • 7
    • 51449116659 scopus 로고    scopus 로고
    • Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma
    • doi: 10.1016/j.ijrobp.2008.05.062
    • Narayana A, Golfinos JG, Fischer I et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383-389. doi: 10.1016/ j.ijrobp.2008.05.062
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , pp. 383-389
    • Narayana, A.1    Golfinos, J.G.2    Fischer, I.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.